JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON: REMDESIVIR AS EFFECTIVE DRUG IN COVID-19 TREATMENT

Rohini S Dongare*[1] , Shraddha B Amate[2], Tejas U Amrute [3]

H.S.B.P.V.T'S GOI COLLEGE OF PHARMACY KASHTI, Ahmednagar,

Maharashtra, India, 414701

Email: rohinidongare7444@gmail.com

ABSTRACT:

The current Severe Acute Respiratory Distress Syndrome (SARS-CoV-2) coronavirus 2 pandemic poses significant health dangers to patients and professionals all around the world. In the covid- 19 epidemic, the antiviral medicine remdesivir is regarded as a "molecule of hope." Under the brand name Vecklury, Remdesivir (GS-5734) is the leading certified medication for extreme coronavirus disease 2019 (COVID-19). It's a one-of-a-kind nucleoside analogue having antiviral properties against Ebola virus (EBOV) and respiratory infections like Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV and SARS-CoV-2. In May 2020, the FDA gave Remdesivir its imprimatur for hospitalized patients. It is the first licensed medicament to be utilized in treatment of the Covid-19. The medicine was initially identified in 2016 and is a derivative of an antiviral library of small compounds designed to prevent the spread of dangerous RNA viruses. Remdesivir reduces the time it takes for hospitalized patients who require auxiliary oxygen to be retrieved and may have an efficacious effect on mortality outcomes while also giving a good protective outline. Remdesivir's analytical determinations were summarized, including mechanism of action, pharmacokinetics, administration, and adverse effects.

KEYWORDS:

Remdesivir, Covid-19, US FDA, SARS-CoV 2, MERS- CoV, Ebola virus, Nucleoside Analogue

INTRODUCTION:

In early 2020, the world was swept away by a wave of a new coronavirus disease known as COVID-19, according to the World Health Organization (WHO) intense acute breathing syndrome coronavirus 2 is the source of this contamination (SARS-CoV-2). The data on remdesivir nucleotide analogue (Gilead Sciences number GS-5734), one of the promising healing medicines, was analyzed. These findings are based on remdesivir activation of the prodrug at the active molecule – triphosphate, which contains the 1'-cyano group and the altered nucleobase. Remdesivir is a nucleotide-analog prodrug that interrupts viral replication and was first tested in clinical studies to stop the Ebola outbreak in 2014. Remdesivir's ability to limit the reproduction of coronaviruses, including SARS-CoV-2, has been shown in subsequent tests by a number of virology labs. Remdesivir is a broad-spectrum antiviral drug manufactured by Gilead Sciences and marketed under the brand name Veklury. It is administered through IV route.

The development of remdesivir has aided in the treatment of COVID-19. It has been approved in approximately 50 nations since 2020. It was created to treat the Ebola virus, but it didn't work. Remdesivir's new indications for treating Ebola, hepatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and cardiovascular

problems have expanded its therapeutic range. Remdesivir in multiplex new creative combinations and delivery modalities is expected to provide superior treatment for COVID-19.

Remdesivir in covid- 19 treatment:

COVID-19 does not have a known therapy. In extreme situations, however, intense palliative care is required to maintain renal function and electrolyte balance while also reducing bleeding and shock. Clinical trials in infected patients have recently indicated that remdesivir (GS-5734) has very positive activity against COVID-19 infection. RDV is excreted in the urine in 74% of cases and in the faces in 18% of cases. The metabolite GS-441524 accounts for 49% of the dose recovered, whereas the unmetabolized parent molecule accounts for 10%.In models based on primary human lung cells and cat cells infected with the coronavirus, GS-441524, the major metabolite of RDV and superior to Remdesivir against Covid-19, demonstrates comparable activity. The coronavirus strain SARS-CoV-2 was studied in vitro in simian or human cells (COVID-19). Remdesivir has been shown in vitro to prevent viral infection when the virus enters the cell.

Mechanism of action of Remdesivir:

Remdesivir is a monophosphoramidate nucleoside prodrug that is converted to its active metabolite nucleoside triphosphate within the cell (NTP) Nucleoside analogues, it is hypothesized, do not readily penetrate the cell wall. After entering the host cell, they undergo phosphorylation to form nucleoside triphosphate (NTP), which is similar to adenosine triphosphate (ATP) and can be used for genome replication by RdRp enzymes or complexes. When remdesivir is metabolized by host cells to its active chemical counterpart, adenosine triphosphate (GS-443902), it competes with ATP for integration of the RdRp complex into the inchoate RNA stand, resulting in the halting of RNA fusion, which restricts viral replication. In vitro studies of SARS-CoV-2 in normal respiratory epithelium and lung cells.



Fig.1 Mode of action of Remdesivir:

Remdesivir demonstrated a dose-dependent inhibitory effect on SARS-CoV-2 replication with a Remdesivir is useful for COVID-19 treatment but uncertain on extremely well-known preclinical findings a priori good security profile. There is currently insufficient data to propose a specific treatment for COVID-19 patients,

according to the majority of clinical practice trials. However, in the event of a health emergency, the researchers advise using other compounds alone or in combination. Remdesivir, which has a broad spectrum of anti-SARS-CoV2 actions, is currently suggested as a potentiate.

Pharmacokinetics:

Following single-cure intravenous administration of remdesivir over 2 hours, remdesivir and its metabolites flashed a right profile across the study cures that ranged from 3 – 225 mg with both answer and response, according to a randomized, bedazzled, placebo-controlled phase I study estimating the pharmacokinetics of single-cure and multiple-cure of remdesivir compared to placebo in healthy subjects. Remdesivir is a substrate for the organic anion transporting polypeptides OATP1B1, OATP1B3, and P-glycoprotein (P P-gp) transporters, as well as the CYP2C8, CYP2D6, and CYP3A4 cytochrome P450 (CYP450 CYP450) transporters. Despite the fact that CYP induction by remdesivir and its metabolites is thought to be a disadvantage of CYP enzymes in vitro, there has been no evidence of CYP induction by remdesivir and its metabolites in vivo. Regardless, it is vital to build clinically significant drug – medication deals (DDIs DDIs) based on its mode of administration and fleet removal. Other clinical investigations, on the other hand, claim to quantify its interactions with the cytochrome P450 system, which would determine the implicit medication-medication interactions with remdesivir.

Table 1. Clinical data of Remdesivir:

Brand name	Vecklury
Other name	GS- 5734
Root of Administration	Intravenous
Category	Antiviral



Fig. 2 Chemical structure of Remdesivir:

Gilead, the US Centers for Disease Control and Prevention and the US Army Medical Research Institute of Infectious Diseases partnered to together invent Remdesivir. C27H35N6O8P is the molecular formula and (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester is a IUPAC name of Remdesivir.

Administration:

It is noted that the bioavailability of remdesivir in animal models was poor by oral route due to almost complete first-pass clearance attributed to poor hepatic stability. When injected intramuscularly, the active drug analogue adenosine triphosphate was delayed (IM). Nonetheless, intravenous administration of radiolabeled remdesivir in rats and monkeys revealed a deep dispersion of radioactivity in the final apkins with the round of the major metabolite GS-441524.As a result, researchers concluded that intravenous (IV) treatment of remdesivir released the active metabolite more quickly than intramuscular or oral administration. After a single intravenous infusion of remdesivir in healthy male subjects, the absolute bioavailability of remdesivir claims to be 100, with easily identifiable ranges of remdesivir in blood and plasma, reaching peak absorption at the end of the infusion. For adults and children with suspected or confirmed COVID-19 infection, the currently recommended remdesivir is suspended weight and administered intravenously.

Adults and pediatric patients aged 12 and above who weigh at least 40 kg get a loading dose of 200 mg IV on day 1, followed by a maintenance dosage of 100 mg IV daily for up to 9 days, depending on the severity of the disease and clinical response to treatment. Remdesivir isn't normally licensed by the FDA or for usage outside of hospitals, and the best treatment duration for COVID-19 is unknown. Even so, if no medical reaction is noted, Remdesivir may be given for 5 days to patients who require invasive mechanical air flow and/or ECMO support.

Adverse effects:

Remdesivir's safety profile has yet to be thoroughly described because it is still considered an experimental medicine. Respiratory failure and blood indicators of organ malfunction, such as low albumin, low red blood cell count, low blood platelet count, and elevated bilirubin, were the most common side events in persons using remdesivir (jaundice). Gastrointestinal problems, elevated blood transaminases (liver enzymes), and infusion site responses are among the other documented adverse effects. According to the studies, bradycardia or hypotension are the most common cardiac abnormalities in COVID-19 patients receiving remdesivir, with QT prolongation being less common. Remdesivir infusions can cause low blood pressure, nausea, vomiting, sweating, and chills, among other things. With a remdesivir infusion or when remdesivir was delivered, infusion-related reactions have been recorded. Increased liver enzyme levels, as shown in abnormal liver blood tests. Increases in liver enzyme levels have been observed in persons who have received remdesivir, which could indicate inflammation or injury to liver cells.

Conclusion:

The use of Remdesivir in the treatment of covid-19 was investigated. Remdesivir was examined for its therapy, mechanism of action, pharmacokinetics, and side effects. Vecklury is the brand name for Remdesivir. It's a monophosphoramidate nucleoside prodrug with antiviral properties against Covid-19. Remdesivir is an example of a drug whose current use may help to minimize the morbidity and death associated with the global pandemic caused by COVID-19.

References:

1) Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clinical microbiology reviews. 2020 Oct 14;34(1):e00162-20.

2) Gupta AK, Parker BM, Priyadarshi V, Parker J. Cardiac adverse events with remdesivir in COVID-19 infection. Cureus. 2020 Oct;12(10).

3) Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clinical epidemiology and global health. 2021 Jan 1;9:123-7.

4) Saqrane S, El Mhammedi MA, Lahrich S, Laghrib F, El Bouabi Y, Farahi A, Bakasse M. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections. Journal of Infection and Public Health. 2021 Feb 20.

5) Michalska K, Kim Y, Jedrzejczak R, Maltseva NI, Stols L, Endres M, Joachimiak A. Crystal structures of SARS-CoV-2 ADP-ribose phosphatase: from the apo form to ligand complexes. IUCrJ. 2020 Sep 1;7(5).

6) Killerby ME, Biggs HM, Haynes A, Dahl RM, Mustaquim D, Gerber SI, Watson JT. Human coronavirus circulation in the United States 2014–2017. Journal of Clinical Virology. 2018 Apr 1;101:52-6.

7) Khanal P. Remdesivir for COVID-19 treatment: mechanism OF action, synthesis, and clinical trials. J PHARM PHARM SCI. 2020 Jun 3.

8) Zarenezhad E, Behrouz S, Farjam M, Rad MS. A Mini Review on Discovery and Synthesis of Remdesivir as an Effective and Promising Drug against COVID-19. Russian Journal of Bioorganic Chemistry. 2021 May;47(3):609-21.
9) Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021(8).
10) Musa A, Pendi K, Hashemi A, Warbasse E, Kouyoumjian S, Yousif J, Blodget E, Stevens S, Aly B, Baron DA. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature. Western Journal of Emergency Medicine. 2020 Jul;21(4):737.
11) de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences. 2020 Mar 24;117(12):6771-6.
12) Matthias G. Remdesivir for the Treatment of Covid-19: The Value of Biochemical Studies. Current Opinion in Virology. 2021 May 12.
13) Jiang Y, Chen D, Cai D, Yi Y, Jiang S. Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis. Journal of medical virology. 2021 Feb;93(2):1171-4.
14) Al-Tannak NF, Novotny L, Alhunayan A. Remdesivir—bringing hope for COVID-19 treatment. Scientia Pharmaceutica. 2020 Jun;88(2):29.
15) Lin HX, Cho S, Aravamudan VM, Sanda HY, Palraj R, Molton JS, Venkatachalam I. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection. 2021 Jan 2:1-0.
16) Nili A, Farbod A, Neishabouri A, Mozafarihashjin M, Tavakolpour S, Mahmoudi H. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Reviews in medical virology. 2020 Nov;30(6):1-3.
17) Mishra D, Maurya RR, Kumar K, Munjal NS, Bahadur V, Sharma S, Singh P, Bahadur I. Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies. Journal of Molecular Liquids. 2021 Aug 1;335:116185.
18) Wikipedia
19) Jung LS, Gund TM, Narayan M. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. The Protein Journal. 2020 Dec;39(6):619-30.
20) Badgujar KC, Ram AH, Zanznay R, Kadam H, Badgujar VC. Remdesivir for COVID-19: A review of pharmacology, mechanism of action, in-vitro activity and clinical use based on available case studies. Journal of Drug Delivery and Therapeutics. 2020 Aug 15;10(4-s):264-70.
21) Taha HR, Keewan N, Slati F, Al-Sawalha NA. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic. Pharmacology. 2021;106(9-10):462-8.
22) Aleem A, Kothadia J. Remdesivir. StatPearls. 2021 Apr 8.
23) US Food and Drug Administration. FDA. Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734). Washington: US Food and Drug Administration; 2020 [acceso 1 mayo 2020].
24) Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS central Science. 2020 May 4;6(5):672-83.
25) Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D. Remdesivir for the treatment of Covid-19. New England Journal of Medicine. 2020 Nov 5;383(19):1813-26.
26) Gillenwater S, Rahaghi F, Hadeh A. Remdesivir for the treatment of covid-19-preliminary report. N Engl J Med. 2020 Jul 10;383(10):992.
27) Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Archives of Medical research. 2020 Aug 1;51(6):585-6.
28) Hendaus MA. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. Journal of Biomolecular Structure and Dynamics. 2020 May 19:1-6.